**Abstract**

Neuropathic pain is a major public health problem for which only few treatments are available. Translational studies showed that melatonin, a neurohormone acting on MT1 and MT2 receptors, has analgesic properties, likely through MT2 receptor. Here, we elucidated the effects of the novel selective melatonin MT2 receptor partial agonist N-{2-\[(3-bromophenyl)-4-fluorophenylamino\]ethyl}acetamide (UCM924) on neuropathic pain animal models and its mechanism of action.

In rat spinal L5-L6 nerve ligation (Kim and Chung's method) and spared nerve injury models (SNI), UCM924 (20--40 mg/kg, s.c.) produce a prolonged antiallodynic effect that is 1) dose-dependent and blocked by the selective MT2 receptor antagonist 4P-PDOT, 2) superior to high doses of melatonin (150 mg/kg) and comparable to gabapentin (100 mg/kg), but 3) without noticeable motor-sedative effects in the rotarod test. Using double staining immunohistochemistry, we found that MT2 receptors are expressed by glutamatergic neurons in the rostral ventrolateral periaqueductal gray (vlPAG). Using *in-vivo* electrophysiology combined to tail flick, we observed that microinjection of UCM924 into the vlPAG decreases tail flick responses, depressing the firing activity of ON cells and activating the firing of OFF cells, an effect MT2 receptor-dependent. Moreover, UCM 924 showed also antinoceptive properties in the hot plate model and in the formalin test. Altogether, these data demonstrate, for the first time, that selective MT2 receptor partial agonists have analgesic properties through modulation of brainstem descending antinociceptive pathways and indicate that MT2 receptors may be a novel target in the treatment of neuropathic pain.
